Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals Inc (NAVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,041
  • Shares Outstanding, K 10,059
  • Annual Sales, $ 1,170 K
  • Annual Income, $ -16,110 K
  • 60-Month Beta 0.66
  • Price/Sales 6.31
  • Price/Cash Flow N/A
  • Price/Book 3.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.05
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/07/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/16
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +1,998,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.66 +8.05%
on 10/14/19
1.39 -48.99%
on 10/29/19
+0.01 (+1.29%)
since 10/11/19
3-Month
0.49 +44.69%
on 08/15/19
1.39 -48.99%
on 10/29/19
+0.18 (+34.08%)
since 08/13/19
52-Week
0.49 +44.69%
on 08/15/19
4.40 -83.89%
on 11/30/18
-3.45 (-82.96%)
since 11/13/18

Most Recent Stories

More News
Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its...

NAVB : 0.67 (-4.29%)
Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage...

NAVB : 0.67 (-4.29%)
Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it...

NAVB : 0.67 (-4.29%)
Thinking about buying stock in Cronos Group, Navidea Biopharmaceuticals, PG&E, Pfizer, or Top Ships?

InvestorsObserver issues critical PriceWatch Alerts for CRON, NAVB, PCG, PFE, and TOPS.

NAVB : 0.67 (-4.29%)
PFE : 36.58 (-1.05%)
PCG : 7.24 (+2.55%)
Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

--Company Continues to Enroll Subjects as Planned to Complete the Phase 2B and Prepare for the Upcoming Phase 3 Trial

NAVB : 0.67 (-4.29%)
Navidea Biopharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that...

NAVB : 0.67 (-4.29%)
Navidea Biopharmaceuticals Announces Receipt of Notice of Award

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced receipt...

NAVB : 0.67 (-4.29%)
LaVoieHealthScience Looks to the Future, Promotes Sharon Correia and Ella Deych

LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced the promotion of two of the agency's senior-level...

NAVB : 0.67 (-4.29%)
Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its...

NAVB : 0.67 (-4.29%)
Navidea Biopharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it...

NAVB : 0.67 (-4.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade NAVB with:

Business Summary

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and...

See More

Key Turning Points

2nd Resistance Point 0.86
1st Resistance Point 0.78
Last Price 0.67
1st Support Level 0.64
2nd Support Level 0.58

See More

52-Week High 4.40
Fibonacci 61.8% 2.91
Fibonacci 50% 2.45
Fibonacci 38.2% 1.98
Last Price 0.67
52-Week Low 0.49

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar